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ABSTRACT 
 
Aims: To assess the epidemiology of UTIs affecting inpatients and outpatients and the antibiotic 
resistance levels, expressed as multiple antibiotic resistance (MAR) indices from the isolated 
species at a tertiary-care hospital in Hungary, during a 10-year study period. 
Study Design: Retrospective microbiological study. 
Place and Duration of Study: 1st of January 2008 - 31st of December 2017 at the University of 
Szeged, which is affiliated with the Albert Szent-Györgyi Clinical Center, a primary- and tertiary-
care teaching hospital in the Southern Great Plain of Hungary. 
Methodology: Antimicrobial susceptibility testing (AST) was performed using disk diffusion 
method and when appropriate, E-tests on Mueller–Hinton agar (MHA) plates. The multiple 
antibiotic resistance (MAR) index of the isolates was determined.  
Results: During the 10-year study period, the Institute of Clinical Microbiology received 21,150 
urine samples from outpatient clinics and 19,325 samples from inpatient departments that turned 
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out to be positive for a significant urinary pathogen. Out of the positive urine samples, E. coli 
represented the overwhelming majority of all positive urine samples. The resistance levels in 
inpatient isolates were higher than in the outpatient isolates (average MAR indices: 0.347 vs. 
0.410, 0.267 vs. 0.435 and 0.318 vs. 0.473 for the E. coli/Klebsiella, CES and Proteae group, 
respectively). 
Conclusion: As the therapeutic options are becoming increasingly limited in the current antibiotic 
resistance climate, more effort should be put into the prudent use of antibiotics and the 
development of novel antimicrobial agents. 
 
 
Keywords: Urinary tract infection; Enterobacteriaceae; Escherichia coli; Klebsiella; CES; proteae; 
multiple antibiotic resistance index; antibiotic. 
 
1. INTRODUCTION  
 
Urinary tract infections (UTIs) are some of the 
most common infections in human healthcare, 
both in community (10–30% of infections in 
primary healthcare) and nosocomial settings 
(30–40%) [1,2]. UTIs are often associated with 
recurrence, complications and sequelae, leading 
to a decrease in the quality of life for the affected 
patients [3]. UTIs are most frequently caused by 
members of the Enterobacteriaceae family (or 
more recently, the Enterobacterales order): 
typical pathogens include uropathogenic 
Escherichia coli and Klebsiella spp., however, 
the Proteus-Providencia-Morganella species  
(the Proteae tribe), Citrobacter-Enterobacter-
Serratia species (so-called CES pathogens) have 
now emerged as increasingly relevant Gram-
negative pathogens [4-7]. Some reports suggest 
that 80% of UTIs are caused by various 
serotypes of E. coli (there are more than 1650 
different serotypes of E. coli, if O, H and K 
antigens are considered). E. coli and Proteus 
spp. possess fimbria, allowing for attachment to 
epithelial cells; the resulting production of IL-6 
and IL-8 causes epithelial cell desquamation. On 
the other hand, Klebsiella spp. produce 
extracellular polysaccharides, and have a role in 
stone formation, due to their urease production. 
Among the Gram-positive bacteria, 
Staphylococcus aureus from urine may indicate 
bacteremia or infection of the kidney, 
Enterococcus spp. may cause uncomplicated 
cystitis in women, while S. saprophyticus may 
cause asymptomatic UTI in young females [1-9]. 
The therapy of UTIs is an increasingly complex 
challenge for clinicians, due to the increasing 
levels of antibiotic resistance [8,9]. The 
emergence of multidrug resistance (MDR) and 
extensive drug resistance (XDR) in urinary 
pathogens, together with pre-existing, genetically 
encoded resistance mechanisms means that 
these pathogens may be resistant to a broad 
range of antibiotics [10,11]. 
Since the beginning of the 21st century,                  
many surveillance reports have been                
published regarding the resistance trends of 
Gram-negative bacteria [12]. Nevertheless, the 
epidemiology and antibiotic susceptibility-
patterns of urinary tract pathogens vary                 
greatly by region, and, therefore, the assessment 
of local data is essential to evaluate trends               
over time and to reflect on the national                
situation compared to international data. In 
addition, the knowledge of the relevant antibiotic 
susceptibility patterns of the major bacterial 
pathogens for UTIs is critically important for the 
optimal choice for antibiotic therapy. With this in 
mind, the aim of this study was to assess the 
epidemiology of UTIs affecting inpatients and 
outpatients and the antibiotic resistance levels, 
expressed as multiple antibiotic resistance 
(MAR) indices from the isolated species at the 
Albert Szent-Györgyi Clinical Center (Szeged, 
Hungary) retrospectively, during a 10-year study 
period. 
 
2. MATERIALS AND METHODS 
 
2.1 Study Design, Data Collection 
 
The present retrospective study was carried out 
using microbiological data collected from the 1st 
of January 2008 and 31
st
 of December 2017 at 
the University of Szeged, which is affiliated with 
the Albert Szent-Györgyi Clinical Center, a 
primary- and tertiary-care teaching hospital in the 
Southern Great Plain of Hungary. The Clinical 
Center has a bed capacity of 1820-beds and 
annually serves more than 400,000 patients in 
the region, according to the data of the 
Hungarian National Health Insurance Fund 
(NEAK), including GP-level care, all the way to 
specialized medical interventions [13]. Electronic 
search in the records of the MedBakter 
laboratory information system (LIS) for       
positive urine samples was conducted by the 
author. 
 
 
 
 
Gajdács; JPRI, 29(3): 1-7, 2019; Article no.JPRI.51055 
 
 
 
3 
 
Samples with clinically significant colony counts 
for the abovementioned bacteria (105 < colony 
forming units [CFU]/mL; however, this was 
subject to interpretation, based on the 
information provided on the request forms for 
microbiological analysis and relevant 
international guidelines, e.g., presence of 
underlying conditions in the genitourinary tract) 
were included in the data analysis. Only the first 
isolate per patient was included in the study, 
however, isolates with different antibiotic-
susceptibility patterns were considered as 
different individual isolates [14].  
 
2.2 Identification of Isolates 
 
10 µL of each un-centrifuged urine sample was 
cultured on UriSelect chromogenic agar plates 
(Bio-Rad, Berkeley, CA, USA) with a calibrated 
loop, according to the manufacturer’s instructions 
and incubated at 37ºC for 24–48 h, aerobically. If 
the relevant pathogens presented in significant 
colony count, the plates were passed on for 
further processing. Between 2008–2012, 
presumptive phenotypic (biochemical reaction-
based) methods and VITEK 2 ID (bioMérieux, 
Marcy-l’Étoile, France) were used for bacterial 
identification, while after 2013, this was 
complemented by matrix-assisted laser 
desorption/ionization time-of-flight mass 
spectrometry (MALDI-TOF MS; Bruker Daltonik 
Gmbh. Gr., Bremen, Germany) [5-7]. The 
methodology of sample preparation for MALDI-
TOF MS measurements was described 
elsewhere [15]. Mass spectrometry was 
performed by the Microflex MALDI Biotyper 
(Bruker Daltonics, Bremen, Germany) in positive 
linear mode across the m/z range of 2 to 20 kDa; 
for each spectrum, 240 laser shots at 60 Hz in 
groups of 40 shots per sampling area were 
collected. The MALDI Biotyper RTC 3.1 software 
(Bruker Daltonics) and the MALDI Biotyper 
Library 3.1 were used for spectrum analysis. 
 
2.3 Antimicrobial Susceptibility Testing 
 
Antimicrobial susceptibility testing (AST) was 
performed using disk diffusion method and when 
appropriate, E-tests (Liofilchem, Abruzzo, Italy) 
on Mueller–Hinton agar (MHA) plates. For the 
verification of questionable results, VITEK 2 AST 
(bioMérieux, Marcy-l’Étoile, France) was also 
used. The interpretation of the results was based 
on EUCAST breakpoints. Staphylococcus aureus 
ATCC 29213, Enterococcus faecalis ATCC 
29212, Proteus mirabilis ATCC 35659, 
Escherichia coli ATCC 25922, Klebsiella 
pneumoniae ATCC 700603 and Pseudomonas 
aeruginosa ATCC 27853 were used as quality 
control strains. The following antibiotics were 
tested: norfloxacin, ciprofloxacin, levofloxacin, 
ampicillin, amoxicillin/clavulanic acid, ceftriaxone, 
cefepime, meropenem, doxycycline, gentamicin, 
tobramycin, amikacin, fosfomycin, 
sulfamethoxazole/trimethoprim and 
nitrofurantoin, which is a total of 15 antibiotics 
(excluding cases where intrinsic non-
susceptibility was present; namely in Citrobacter-
Enterobacter-Serratia [n=12 antibiotics] and 
Morganella-Proteus-Providencia [n=10 
antibiotics]) [5-7]. During data analysis, 
intermediate-susceptible results were grouped 
with and reported as resistant. The multiple 
antibiotic resistance (MAR) index of the isolates 
was determined using the formula: MAR Index = 
Number of antibiotics isolate is resistant 
to/Number of antibiotics tested, as described 
previously [16]. The MAR index may range 
between 0.0-1.0.  
 
2.4 Statistical Analysis 
 
Descriptive statistical analysis (including means 
or medians with ranges and percentages to 
characterize data) was performed using 
Microsoft Excel 2013 (Redmond, WA, USA, 
Microsoft Corp.).  
 
3. RESULTS AND DISCUSSION 
 
During the 10-year study period, the Institute of 
Clinical Microbiology received 21,150 urine 
samples from outpatient clinics and 19,325 
samples from inpatient departments that                
turned out to be positive for a significant              
urinary pathogen. The distribution of 
Enterobacteriaceae isolates among inpatient and 
outpatient samples is presented in Table 1. Out 
of the positive urine samples, E. coli represented 
the overwhelming majority of all positive urine 
samples (56.75 ± 4.86% [range: 46.83–65.98%, 
lowest in 2008, highest in 2010] for outpatients, 
while 42.29 ± 2.94% [range: 37.19–45.73%, 
lowest in 2015, highest in 2010] for inpatients), 
followed by Klebsiella spp., members of the 
Proteae tribe and Citrobacter-Enterobacter-
Serratia species.  
 
The MAR indices of the different Gram-negative 
uropathogens are presented in Tables 2-4. In all 
three groups, the resistance levels in inpatient 
isolates were higher than in the outpatient 
isolates (average MAR indices: 0.347 vs. 0.410, 
0.267 vs. 0.435 and 0.318 vs. 0.473 for the
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Table 1. Species-distribution of urinary pathogens in the Enterobacteriaceae family in a tertiary-care hospital in Hungary (2008-2017) 
 
Species Outpatients (average±SD; 
%) 
Inpatients (average±SD;%) Outpatients (range;%), 
highest and lowest years 
Inpatients (range;%), 
highest and lowest years 
E. coli 56.7 ± 4.8 42.2 ± 2.9 46.8-65.98 (2008; 2010) 37.2-45.7 (2012; 2011) 
K. pneumoniae 8.9 ± 2.3 13.4 ± 2.2 2.9-10.4 (2012; 2011) 9.5-15.3 (2008; 2011) 
K. oxytoca 1.4 ± 0.3 1.16 ± 0.2 0.7-1.8 (2008; 2011) 0.7-1.8 (2008; 2011) 
CES group 
(Citrobacter-Enterobacter-Serratia) 
5.0 ± 0.9 7.2 ± 1.7 3.6-6.3 (2010; 2017) 3.5-9.6 (2009; 2015) 
Proteae group 
(Morganella-Proteus-Providencia) 
2.6 ± 0.1 3.0 ± 0.4 1.9-3.2 (2012; 2017) 2.5-3.8 (2015; 2013) 
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E. coli/Klebsiella, CES and Proteae group, 
respectively), additionally, the highest frequency 
of isolates in the relevant MAR indices were also 
corresponding to higher MAR-index values (MAR 
indices: 0.335 vs. 0.536, 0.249 vs. 0.498 and 
0.300 vs. 0.400 for the E. coli/Klebsiella, CES 
and Proteae group, respectively). 
 
The increasing levels of antimicrobial drug 
resistance in urinary tract infection correspond to 
both local and international changes in treatment 
guidelines. MDR Gram-negatives leads to poor 
prognoses and an increased complication       
rate, mortality rate, especially in nosocomial 
settings [17]. The abovementioned urinary 
pathogens were most frequently resistant to the 
fluoroquinolones, sulfamethoxazole/trimethoprim 
and ampicillin therefore; the empiric use of these 
agents should be discouraged [18]. The therapy 
of Proteae and CES infections is especially 
challenging due to the various intrinsic resistance 
mechanisms these pathogens possess [19,20]. 
In addition, some last-resort drugs used in 
clinically relevant infections with Gram-negative 
pathogens, like tigecycline and colistin are not 
useful in the therapy of Proteae-associated
 
Table 2. Multiple antibiotic resistance (MAR) index of E. coli and Klebsiella spp. isolated from 
urinary tract infections in a tertiary-care hospital in Hungary (2008-2017) 
 
MAR index (a/b)* Outpatient isolates frequency (%) Inpatient isolates frequency (%) 
0.000 12.1 4.3 
0.067 0.2 0.8 
0.133 0.3 1.4 
0.201 13.4 7.6 
0.268 5.3 9.4 
0.335 26.9 14.6 
0.402 14.3 16.8 
0.469 8.8 10.2 
0.536 6.4 24.1 
0.603 5.2 6.0 
0.670 3.6 1.0 
0.737 2.0 0.8 
0.804 1.0 1.8 
0.871 0.5 1.2 
0.938 0.0 0.0 
1.000 0.0 0.0 
*Number of antibiotics tested: n=15 
Boldface: the highest ratio of representative strains; Underlined: highest MAR level in the group 
 
Table 3. Multiple antibiotic resistance (MAR) index of CES pathogens (Citrobacter-
Enterobacter-Serratia) isolated from urinary tract infections in a tertiary-care hospital in 
Hungary (2008-2017) 
 
MAR index (a/b)* Outpatient isolates frequency (%) Inpatient isolates frequency (%) 
0.000 16.3 4.2 
0.083 4.6 6.6 
0.166 4.2 10.3 
0.249 38.9 9.4 
0.332 14.9 10.1 
0.415 3.5 17.8 
0.498 10.1 26.4 
0.581 6.0 14.1 
0.664 1.0 8.8 
0.747 0.3 1.0 
0.830 0.2 0.3 
0.913 0.0 0.0 
1.000 0.0 0.0 
*Number of antibiotics tested: n=12 
Boldface: the highest ratio of representative strains; Underlined: highest MAR level in the group 
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Table 4. Multiple antibiotic resistance (MAR) index of Proteae (Morganella-Proteus-
Providencia) isolated from urinary tract infections in a tertiary-care hospital in Hungary (2008-
2017) 
 
MAR index (a/b)* Outpatient isolates frequency (%) Inpatient isolates frequency (%) 
0.000 3.2 1.8 
0.100 8.6 2.6 
0.200 24.9 10.5 
0.300 25.3 13.7 
0.400 17.7 19.9 
0.500 15.4 16.3 
0.600 1.2 12.4 
0.700 2.0 12.8 
0.800 1.0 6.7 
0.900 0.7 3.3 
1.000 0.0 0.0 
*Number of antibiotics tested: n=10 
Boldface: the highest ratio of representative strains; Underlined: highest MAR level in the group 
 
pathologies and some beta-lactam antibiotics 
and colistin are not useful against Serratia spp. 
Intrinsic non-susceptibility to several drug groups 
severely limits the number of therapeutic 
alternatives, especially for outpatient care. 
Nitrofurantoin and fosfomycin (if susceptibility is 
confirmed) represents a safe and viable option 
for the treatment of these infections [9]. 
 
4. CONCLUSION 
 
This study presents a current epidemiological 
snapshot and resistance levels of 
Enterobacteriaceae associated with of urinary 
tract infections (UTIs) in Hungary over a long 
period (2008-2017). To the best of the authors 
knowledge, this is the first study in Hungary, 
reporting on the resistance levels of these 
pathogens using the MAR index. As the 
therapeutic options are becoming increasingly 
limited in the current antibiotic resistance climate, 
more effort should be put into the prudent use of 
antibiotics and the development of novel 
antimicrobial agents. 
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